Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq Analysis of Hinokitiol-Treated LUAD Cells

ABSTRACT: A549 and HCC827 cells were treated with Hinokitiol (20 μM) or DMSO for 24 hours and subjected to RNA-seq analysis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE294762 | GEO | 2025/06/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNAseq Analysis in glioblastoma cells treated with Mepazine

Project description:Glioblastoma cells were treated with vehicle (DMSO) or mepazine (MPZ, 20 μM, 4 hours) and prepared for RNAseq according to ActiveMotif standard procedure. The list of differentially expressed genes from DESeq2 output was selected based on 10% adjusted p-value level and FDR of 0.1.

2019-10-18 | GSE139018 | GEO

RNA-seq in MaV208 WT and mutant Saccharomyces cerevisiae yeast strains treated with DMSO, TSA, or E6R

Project description:As part of a larger study identifying novel HDAC complex inhibitors, WT cells were treated with DMSO, 20 μM TSA or 50 μM E6R to investigate changes in gene expression levels. Also, cultures of rpd3Δ and sin3Δ mutant strains treated with DMSO were investigated.

2025-08-22 | GSE211775 | GEO

RNA-seq analysis of A549 cells treated with chrysin or nifurtimox

Project description:The influences of 40 hours treatment of 30 μM chrysin (CAS No: 480-40-0) or 30 μM nifurtimox (CAS No: 23256-30-6) on A549 cell gene expression profile were examined by RNA sequencing.

2022-03-01 | GSE193541 | GEO

RNA-sequencing of Mycobacterium tuberculosis treated with C10

Project description:We sought to identify pathways dysregulated in Mycobacterium tuberculosis upon treatment with the compound C10. We treated M. tuberculosis with DMSO, 5 μM C10, or 25 μM C10 for 48 hours in Sauton's medium and used RNA-sequencing to compare transcriptional profiles.

2019-05-31 | GSE129833 | GEO

The HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR mutated and wildtype NSCLC cells

Project description:Background: The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib. Chromatin-modifying agents may offer a novel therapeutic approach by sensitizing tumor cells to TKIs. Methods: The NSCLC cell lines HCC827 (EGFR mutant, adenocarcinoma), A549 (EGFR wt, adenocarcinoma) andNCI-H460 (EGFR wt, large cell carcinoma) were analyzed by SNP6.0 array. Changes in proliferation after panobinostat (LBH-589, PS) and erlotinib treatment were quantified by WST-1 assay and apoptosis by Annexin V/7-AAD flow cytometry. Abundance of target proteins and histone marks (acH3, H3K4me1/2/3) was determined by immunoblotting. Results: As expected, the EGFR wt cell lines A549 and NCI-H460 were quite insensitive to the growth-inhibitory effect of single-agent erlotinib (IC50 70-100 μM), compared to HCC827 (IC50 < 0.02 μM). PS treatment diminished growth to <50 % in both EGFR wt cells, and <30 % in HCC827. The combination of both drugs reduced proliferation by >95 % in HCC827, ≥70 % in A549, but not further in NCI-H460. PS alone induced differentiation and expression of p21WAF1/CIP1 and p53 and decreased CHK1 in all three cell lines, with almost no further effect when combined with erlotinib. In contrast, combination treatment additively decreased pEGFR, pERK, pAKT in A549, and synergistically induced acH3 in both adenocarcinoma lines. Surprisingly, we saw an induction of H3K4 methylation marks after erlotinib treatment in HCC827 (and to a lesser extent in A549) that was even further enhanced by combination with PS. Conclusion: We were able to show that PS synergistically sensitized lung adenocarcinoma cells to the antiproliferative effects of erlotinib. Since single-agent erlotinib has only modest clinical effects in lung adenocarcinoma EGFR wt patients, its combination with an HDACi might offer a promising therapy approach.

2014-12-03 | GSE63784 | GEO

Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines

Project description:Human melanoma cell line A375 and A2058 were incubated with DMSO (control group) or Vemurafenib (1 μM in DMSO) for 72 hours. Total RNA was isolated with Qiagen RNA isolation kit; 1.5 μg of total RNA was used as template for cDNA synthesis.

2015-12-02 | GSE52882 | GEO

Gene expression profiling of triple-negative breast cancer cells by Nitidine Chloride(NCD)

Project description:To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells perturbed by NCD, we treated MDA-MB-231 with either DMSO or 5 μM NCD for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with Nitidine Chloride, we can identify the genes affected by Nitidine Chloride.

2025-12-09 | GSE294840 | GEO

3D + LY vs. 3D culture of HUASMC

Project description:To study the impact of TGF signaling on the transcriptome of vascular smooth muscle cells, we cultured human umbilical artery smooth muscle cells as 3D aggregates in hanging drops for 48 hours. One group was treated with TGFβRI/II inhibitor LY2109761 (10 μM, additional 10 μM after 24 h), the other group with solvent (DMSO) as control. RNA was isolated from both groups after 48h

2019-12-16 | GSE133649 | GEO

Gene expression profiling of triple-negative breast cancer cells and liver cancer cells perturbed by BET inhibitor JQ1

Project description:To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells and liver cancer HepG2 cells perturbed by the BET inhibitor JQ1, we treated MDA-MB-231 and HepG2 cells with either DMSO (control) or 10 μM JQ1 for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with JQ1, we can identify the genes affected by JQ1.

2025-08-22 | GSE294293 | GEO

CSN5i-3 induces degradation of selective CRL substrate receptors and accumulation of CRL substrates

Project description:In this study, we used quantitative proteomics mass spectrometry with 16-plex TMT labeling to compare individual protein levels of DMSO and 1 μM CSN5i-3-treated K562 cells for 2, 8, and 24 hours. CSN5i-3 is a selective and potent inhibitor of Cop9 Signalosome (CSN), which regulates the activity of Cullin-RING E3 ubiquitin ligases (CRLs). CSN5i-3 treatment resulted in reduced CSN activity, and consequently increased cullin neddylation and constitutively active CRL. Gene Ontology analysis of the changed proteins between DMSO- and CSN5i-3-treated samples showed the enrichment of CSN subunits, cell cycle and chromosome-related components, and phosphatase complex, which include multiple CSN subunits (e.g., CSN7B and CSN5), components of CRLs, especially CRL SRs (e.g., SKP2, ELOA and DCAF1/VPRBP), and known substrates of CRLs (e.g., MAGEA6, GLUL, and RHOB). Indeed, eight out of the top 20 most decreased proteins were CRL adaptor and substrate receptors, two out of the top 20 were E2 proteins (CDC34/UBE2R1 and UBE2R2), and two were CSN subunits. Eight out of the top 20 most increased proteins were reported CRL substrates.

2022-09-05 | PXD027862 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data